Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Next Previous
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deuruxolitinib (Primary)
  • Indications Alopecia areata
  • Focus Registrational; Therapeutic Use
  • Acronyms THRIVE-AA1
  • Sponsors Concert Pharmaceuticals

Most Recent Events

  • 25 Jul 2024 According to a Sun Pharmaceutical Industries media release, based on results form two phase 3 studies THRIVE-AA1 and THRIVE-AA2, the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.
  • 21 Mar 2023 Results assessing the safety outcomes of CTP-543 (Deuruxolitinib) in adult patients with moderate to severe alopecia areata, presented at the American Academy of Dermatology annual Meeting 2023.
  • 21 Mar 2023 Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial assessing efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata presented at the American Academy of Dermatology annual Meeting 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top